Tradestie Institutional Equity Comparison Engine

ELVN vs ACAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin while ELVN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ELVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ACAD at 17.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
ELVN N/M vs ACAD 17.8x Fwd P/E
Growth & Margin Winner ACAD
Op Margin 0.0% vs 10.2% ยท YoY +0.0% vs +22.8%
Momentum & Technical Winner ELVN
1Y +134.5% vs -19.3% ยท 52W Pos 69% vs 21%
Options & Structure Winner ELVN
CONSOLIDATION (5th %ile IV) vs BREAKDOWN (4th %ile IV)
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
1M Return +27.38%
1Y Return +134.53%
Forward P/E N/M
Unified AI Score
35.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 60.0
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$19.07
+1.71% 1D
Market Cap $3.1B
1M Return -0.26%
1Y Return -19.33%
Forward P/E 17.8x
Unified AI Score
46.7 / 100 HOLD
Tech 41.0 Fund 52.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ELVN +134.53% ACAD -19.33% Spread: +153.86 pp (ELVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ELVN TTM Op. Margin: 0.0% ACAD TTM Op. Margin: 10.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs ACAD. Trailing 12-month operating profitability (ELVN 0.0% vs ACAD 10.2%) and valuation multiples (ELVN N/M vs ACAD 17.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ELVN (3) vs ACAD (7)
Institutional Metric ELVN ACAD Criterion Row Winner
Market Capitalization Scale $3.6B $3.1B Larger Scale ELVN
Trailing P/E Ratio Valuation N/M 8.6x Lower Multiple ACAD
Forward P/E Ratio Valuation N/M 17.8x Lower Multiple ACAD
Revenue Growth (YoY) Growth +0.0% +22.8% Higher Growth ACAD
Operating Margin (TTM) Profitability 0.0% 10.2% Higher Margin ACAD
Net Profit Margin Profitability 0.0% 30.1% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency -16.8% 31.4% Higher ROE ACAD
52-Week Range Position Momentum 69% ($15โ€“$62) 21% ($16โ€“$31) Stronger Trend ELVN
Beta / 30D Volatility Risk Regime 0.96ฮฒ ยท 60% Vol 0.11ฮฒ ยท 93% Vol Lower Realized Risk ELVN
Unified Institutional Score Composite Signal 35.9 / 100 (SELL) 46.7 / 100 (HOLD) Higher Composite ACAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ELVN vs ACAD Buy Guide
ELVN CONSOLIDATION
59d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live ELVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ELVN nor ACAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.